Dr. Mark Packer MD
Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
Member of the Healthcare Council
Council Member Biography
Mark Packer, MD, FACS, is Clinical Associate Professor of Ophthalmology at Oregon Health & Sciences University. He is also in private practice with Drs. Fine and Hoffman in Eugene, OR. Dr. Packer's research focuses on refractive surgery, intraocular lens technology and glaucoma surgical devices. He serves as Principal Investigator for the Carl Zeiss Meditec MEL-80 Excimer Laser and as Medical Monitor for the US FDA study of the aspheric Tecnis Multifocal Intraocular Lens. Dr. Packer is also Principal Investigator for the Visiogen Synchrony Dual Optic Accommodative Lens and Medical Monitor for Transcend Medical's CyPass glaucoma shunt. He works extensively with leaders in the ophthalmic industry on the development of new technology for cataract and refractive surgery and he is a consultant to Abbott Medical Optics, Advanced Vision Science, General Electric Company, Rayner Intraocular Lenses, Transcend Medical, TrueVision Systems, Visiogen, and WaveTec Vision Systems. (This is me - Update Profile)
Employment History
- 2001 - Unspecified
- Clinical Associate Professor of Ophthalmology, OREGON HEALTH & SCIENCE UNIVERSITY - CC
- 2000 - Unspecified
- Owner, DR'S FINE HOFFMAN & PACKER LLC
GLG NewsSM Analyses by Mark Packer(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Tecnis Multifocal Outperforms Competitors
September 20, 2009
Summary of Safety and Effectiveness Data (FDA) | www.fda.gov
The US Clinical Investigation of the Tecnis Multifocal demonstrated 88% complete freedom from glasses at 6 months, and 95% satisfaction at one year. A comparable study of the ReStor lenses, with both 3 and 4 diopter adds, demonstrated 76% freedom from glasses at 4 - 6 months. Despite a one line lower performance at intermediate range for the Tecnis the overall results favor its adoption for providing presbyopia correction after cataract surgery.
-
AMO Grows Portfolio, Potential with Acquisition of Accommodating Lens Implant
September 3, 2009
Abbott to Acquire Visiogen, Expanding Vision Care Portfolio | www.abbott.com
It was announced today that Abbot Labs intends to acquire Visiogen (Santa Ana, CA) for $400 million in cash. Earlier this year Abbott acquired Advanced Medical Optics, manufacturer of the Tecnis Multifocal IOL and the VISX excimer laser. Visiogen's accommodating IOL, called Synchrony, is designed to deliver improved vision at all distances, potentially eliminating the need for glasses. Visiogen has obtained he CE Mark. FDA approval is pending and is expected in mid 2010.
-
Tecnis Multifocal FDA Data Shatters the Bifocal Glasses Ceiling
April 1, 2009
Summary of Safety and Effectiveness Data (FDA) | www.fda.gov
The approval of the Tecnis Multifocal IOL represents an exciting new alternative for patients in the United States with cataracts and those presbyopic individuals who desire spectacle independence. With the highest level of subjects who never wear glasses ever reported in an FDA monitored investigation, the Tecnis Multifocal heads to the front of the pack of the multifocal, presbyopia correcting IOLs. The crystalens (B & L, Rochester, NY) remains the only approved accommodative IOL in the United States.
-
Refractive Cataract Surgery's Holy Grail: Keep it in Sight
March 2, 2009
Lens refilling to restore accommodation | www.sciencedirect.com
The concept of re-filling the empty lens capsule following lens or cataract extraction with an elastic substance that mimics the accommodative function of the youthful human lens remains a captivating concept for researchers. Nishi's review article highlights the progress so far in this direction, as well as the challenges inherent in development of a successful design. These challenges include sealing the capsule to prevent leakage of the injectable material, adjusting the refractive state for emmetropia, allowing adequate accommodative amplitude and preventing capsular opacification.
-
Visian ICL: Premium Channel for the Extremely Nearsighted
August 19, 2008
Insiders Buy Staar as Lasik Alternate Shows Potential (Update2) | www.bloomberg.com
The Visian ICL (Implantable Collamer Lens) is an exquisitely precise technology for the correction of high degrees of nearsightedness -- much higher than the reach of laser refractive surgery such as LASIK and PRK. Given the price of the ICL and the intraocular surgey required for its implantation, the out-of-pocket expense for the patient is about US$4000 per eye (about double the average LASIK). In general, if patients are candidates for LASIK they will have LASIK; it is only those who cannot have LASIK because of their extreme nearsightedness who opt for the ICL. LASIK works extremely well in the low to moderate nearsightedness range, and it corrects astigmatism as well (there is a toric ICL, but it is not yet approved in the United States).
Leading institutions connect with Mark Packer through GLG
GLG Study Groups with Mark Packer(?)
| Study Group Name | No. Members |
|---|---|
| Ophthalmologists | 1610 |
| Physicians who Implant Intraocular Lenses | 217 |
| LASIK Surgeons | 186 |
| Cataract Surgeons (US) | 111 |
| Ophthalmologists who Implant Tecnis Intraocular Lens | 46 |
GLG Live Meetings with Mark Packer(?)
Mark Packer has not participated in any GLG Live Meetings.